VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

Confusing data come out from early intensification ABMT programs in
poor risk patients (78)
and certainly in the future an adequate randomized trial
should be planned. The exact role of high dose chemotherapy in refractory patients
sensitive to salvage chemotherapy may be established only in a phase HI
trial.
In Europe a randomized trial is planned from spring 1993. After two courses
of reinduction chemotherapy (VelP or VIP according to single centre's choice)
only patients with sensitive tumors will be randomized to two more courses of
the same regimen versus two courses plus one single CarboPEC shot
(Carboplatin 1,600 mg/sqm, VP161,750 mg/sqm, Cyclophosphamide 6.4 gr/
sqm). A total of 200 patients are expected to be registered, and assuming a non
response rate of 20%, 80 patients per armwill be randomized.
ACKNOWLEDGEMENTS.
This work was supported by the Istituto Oncologico Romagnolo grant no.
92282.2
REFERENCES
1) Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors
with cisplatin, bleomycin and either vinblastine or etoposide. N Eng J Med 316:1435-
1440,1987.
2) Saxman S: Salvage therapy in recurrent testicular cancer. Sem Oncol 19(2):143-
147,1992.
3) Gratwohl A, Herman J, Goldman J,et al: Bone marrow transplantation in Europe:
major geographical differences. J Int Med (in press)
4) Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective
evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-
1756,1992.
5) Linkesch W, Krainer M, Wagner A: Phase I/II trial of ultrahigh carboplatin,
etoposide, cyclophosphamide with ABMT in refractory or relapsed nonseminomatous
germ cell tumors (NSGCT). Proc ASCO 600,1992.
6) Broun ER, Nichols CR, Kneebone P, et al: Long term outcome of patients with
relapsed and refractory germ cell tumors treated with high-dose chemotherapy and
autologous bone marrow rescue. Ann Int Med 117(2):124-128,1992.
7) Motzer RJ, Gulati SC, Crown JP et al: High-dose chemotherapy and autologous bone
marrow rescue for patients with refractory germ cell tumors. Cancer 69:550-556,1992.
8) Droz JP, Pico JL, Biron P, et al: No evidence of a benefit of early intensification
chemotherapy (HDCT) with autologous bone marrow transplantation (ABMT) in
front line treatment of poor risk non seminomatous germ cell tumors (NSGCT):
preliminary results of a randomized trial. Proc ASCO, 602,1992.
SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION 159